Table II. Clinical information of patient samples used for Western Blotting verification.
| Sample # | Age | Pre-op serum PSA (ng/ml) | T-stage | Gleason | Prostate vol (cm3) | % cancer |
|---|---|---|---|---|---|---|
| Biochemical recurrence | ||||||
| 1 | 64 | 4.8 | T1c | 3 + 3 | 31 | 2 |
| 2 | 57 | 4.6 | T2a | 3 + 4 | 40 | 15 |
| 3 | 64 | 37.5 | T2b | 4 + 3 | 53 | 75 |
| 4 | 58 | 8.9 | T2c | 3 + 4 | 41 | 40 |
| 5 | 56 | 4.1 | T2b | 4 + 3 | 30 | 30 |
| No evidence of recurrence | ||||||
| 1 | 61 | 7.8 | T2a | 3 + 3 | 38 | 10 |
| 2 | 64 | 1.3 | T2a | 3 + 3 | 36 | 5 |
| 3 | 62 | 3.6 | T1c | 3 + 3 | N/A | <2 |
| 4 | 51 | 4.6 | T1c | 3 + 3 | 45 | 5 |
| 5 | 58 | 4.5 | T1c | 3 + 3 | 57 | <5 |
| 6 | 55 | 6.7 | T1c | 3 + 4 | 26 | 3 |
| 7 | 67 | 7.3 | T1c | 3 + 4 | 56 | 2 |
| 8 | 53 | 5.2 | T1c | 3 + 4 | 30 | 15 |
| 9 | 50 | 5.7 | T2a | 3 + 3 | 35 | 30 |
| 10 | 61 | 10.4 | T1c | 3 + 4 | 31 | 15 |